Claims

Please amend the claims as follows:

Please cancel claims 1-11 and 13-18, 20-27, 29-33, 35, and 39-41 without prejudice.

Please add the following new claims:

--42. (NEW) A method of proliferating photoreceptor cells in a patient comprising administering to a patient a polypeptide comprising amino acids 108 to 233 of SEQ ID NO:2.

43. (NEW) The method of claim 42, wherein the polypeptide is attached to a water soluble polymer.

44. (NEW) The method of claim 43, wherein the water soluble polymer is polyethylene glycol.

45. (NEW) The method of claim 42, wherein the polypeptide is administered as a pharmaceutical composition.

46. (NEW) The method of claim 45, wherein the polypeptide pharmaceutical composition is a sustained-release pharmaceutical composition.

47. (NEW) The method of claim 42, wherein the polypeptide is administered as a topical pharmaceutical composition.

48. (NEW) The method of claim 42, wherein the polypeptide is administered as an oral pharmaceutical composition.

49. (NEW) The method of claim 42, wherein the polypeptide is administered as a parenteral pharmaceutical composition.

50. (NEW) The method of claim 42, wherein the polypeptide is administered at a dose between about 0.005 mg/kg and about 50 mg/kg body weight.

51. (NEW) The method of claim 50, wherein the polypeptide is administered at a dose between about 0.05 mg/kg and about 5 mg/kg body weight.

B1 CONT'

52. (NEW) The method of claim 42, wherein the polypeptide comprises amino acids 80 to 202 of SEQ ID NO:2.

53. (NEW) The method of claim 52, wherein the polypeptide is attached to a water soluble polymer.

54. (NEW) The method of claim 53, wherein the water soluble polymer is polyethylene glycol.

55. (NEW) The method of claim 52, wherein the polypeptide is administered as a pharmaceutical composition.

56. (NEW) The method of claim 55, wherein the polypeptide pharmaceutical composition is a sustained-release pharmaceutical composition.

57. (NEW) The method of claim 52, wherein the polypeptide is administered as a topical pharmaceutical composition.

58. (NEW) The method of claim 52, wherein the polypeptide is administered as an oral pharmaceutical composition.

59. (NEW) The method of claim 52, wherein the polypeptide is administered as a parenteral pharmaceutical composition.

B1 CONT'

60. (NEW) The method of claim 52, wherein the polypeptide is administered at a dose between about 0.005 mg/kg and about 50 mg/kg body weight.

61. (NEW) The method of claim 60, wherein the polypeptide is administered at a dose between about 0.05 mg/kg and about 5 mg/kg body weight.

62. (NEW) The method of claim 42, wherein the polypeptide comprises amino acids 9 to 396 of SEQ ID NO:2.

63. (NEW) The method of claim 62, wherein the polypeptide is attached to a water soluble polymer.

64. (NEW) The method of claim 63, wherein the water soluble polymer is polyethylene glycol.

65. (NEW) The method of claim 62, wherein the polypeptide is administered as a pharmaceutical composition.

66. (NEW) The method of claim 65, wherein the polypeptide pharmaceutical composition is a sustained-release pharmaceutical composition.

67. (NEW) The method of claim 62, wherein the polypeptide is administered as a topical pharmaceutical composition.

68. (NEW) The method of claim 62, wherein the polypeptide is administered as an oral pharmaceutical composition.

69. (NEW) The method of claim 62, wherein the polypeptide is administered as a parenteral pharmaceutical composition.

70. (NEW) The method of claim 62, wherein the polypeptide is administered at a dose between about 0.005 mg/kg and about 50 mg/kg body weight.

71. (NEW) The method of claim 70, wherein the polypeptide is administered at a dose between about 0.05 mg/kg and about 5 mg/kg body weight.--